The aplastic anemia global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Aplastic Anemia Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The aplastic anemia market size has grown strongly in recent years. It will grow from $6.26 billion in 2023 to $6.63 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to an increase in the prevalence of blood disorders, the rise in awareness about aplastic anemia and blood disorders, the surge in the initiatives by public and private organizations, the rise in the demand for specific treatment and increase in the prevalence of bone marrow disease.
The aplastic anemia market size is expected to see strong growth in the next few years. It will grow to $8.36 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to higher prevalence among elderly populations, favorable regulatory policies supporting drug development, patient advocacy and support groups, comprehensive epidemiological studies, and increasing awareness and diagnosis. Major trends in the forecast period include the development of gene-editing technologies, telemedicine and remote monitoring, biomarker development, biologics and monoclonal antibodies, and patient-specific therapies.
Order your report now for swift delivery @
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers –
Growing healthcare expenditure is expected to propel the growth of the aplastic anemia market going forward. The rise in healthcare expenditure is primarily driven by factors such as aging populations and increasing chronic diseases requiring costly treatments. Healthcare expenditures support aplastic anemia treatment through funding for specialized medical facilities, advanced therapies, and research into effective treatments. For instance, in May 2023, according to the Office for National Statistics, a UK-based national statistical institute, the United Kingdom spent $356.39 billion (£280.7 billion) on healthcare in 2021, amounting to $5318 (£4,188) per person, which represented 12.4% of the country’s GDP, a slight increase from the previous year. Government-financed healthcare spending reached $295.96 billion (£233.1 billion), growing by 9.6% in real terms and constituting 83.0% of total healthcare expenditure. Therefore, the growing healthcare expenditure is driving the growth of the aplastic anemia market.
Driving Growth In The Aplastic Anemia Market
The growing demand for personalized medicines is expected to propel the growth of the aplastic anemia market going forward. Personalized medicine refers to tailoring medical treatment to the individual characteristics of each patient, often based on genetic or molecular profiling. The rise in demand for personalized medicine is driven by advancements in genetic testing and molecular diagnostics. Personalized medicine in aplastic anemia involves tailored treatments based on genetic and molecular profiles to optimize outcomes for individual patients. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicines is driving the growth of the aplastic anemia market.
Market Trends –
Major companies operating in the aplastic anemia market are adopting a strategic partnership approach to enhance research, expand treatment options, and improve patient outcomes. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in February 2022, Hemanext Inc., a US-based biomedical technology company, partnered with The Aplastic Anemia and MDS International Foundation (AAMDS), a US-based nonprofit health organization, to support patients living with aplastic anemia, myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. Through this partnership, Hemanext will work with AAMDS to advance its mission of providing answers, support, and hope to thousands of patients and their families living with bone marrow failure diseases.
The aplastic anemia market covered in this report is segmented –
1) By Disease Type: Acquired Aplastic Anemia, Inherited Bone Marrow Failure Syndromes
2) By Treatment Type: Bone Marrow Transfusion Or Stem Cell Therapy, Blood Transfusion, Drug Therapy
3) By Route Of Administration: Oral, Parentals, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Get an inside scoop of the aplastic anemia market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the aplastic anemia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aplastic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the aplastic anemia market are Pfizer Inc., Johnson & Johnson Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceuticals Co. Ltd., UCB SA, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Cellenkos Inc., Amyndas Pharmaceuticals S.A., Hemogenyx Pharmaceuticals plc, Gamida Cell Ltd.
Table of Contents
1. Executive Summary
2. Aplastic Anemia Market Report Structure
3. Aplastic Anemia Market Trends And Strategies
4. Aplastic Anemia Market – Macro Economic Scenario
5. Aplastic Anemia Market Size And Growth
…..
27. Aplastic Anemia Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix